ArticleJournal of virology2014
Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus.
Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 111 citations in OpenAlex.
- Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.The Journal of infectious diseases · 2016Trial
- Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses.Proceedings of the National Academy of Sciences of the United States of America · 2016Trial
- Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.Human vaccines & immunotherapeutics · 2015Trial
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.Journal of virology · 2026Article
- Application of Humanized MHC Transgenic Mice in the Screening of HLA-Restricted T Cell Epitopes for Influenza Vaccines.Vaccines · 2025Article
- Scientific highlights of the 9th ESWI Influenza Conference.One health outlook · 2024Article
- Increasing HbA1c is associated with reduced CD8Cellular and molecular life sciences : CMLS · 2024Article
- CD8Clinical & translational immunology · 2024Article
- Review
- A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets.Science advances · 2022Article
- Article
- Homologous peptides derived from influenza A, B and C viruses induce variable CD8Clinical & translational immunology · 2022Article
- Influenza Vaccines: Successes and Continuing Challenges.The Journal of infectious diseases · 2021Article
- Review
- Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic.Frontiers of medicine · 2021Review
- Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein.Vaccines · 2021Article
- CD8Nature communications · 2021Article
- Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients.Nature communications · 2021Article
- Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity.PLoS pathogens · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In February 2013, zoonotic transmission of a novel influenza A virus of the H7N9 subtype was reported in China. Although at present no sustained human-to-human transmission has been reported, a pandemic outbreak of this H7N9 virus is feared. Since neutralizing antibodies to the hemagglutinin (HA) globular head domain of the virus are virtually absent in the human population, there is interest in identifying other correlates of protection, such as cross-reactive CD8(+) T cells (cytotoxic T lymphocytes [CTLs]) elicited during seasonal influenza A virus infections. These virus-specific CD8(+) T cells are known to recognize conserved internal proteins of influenza A viruses predominantly, but it is unknown to what extent they cross-react with the newly emerging H7N9 virus. Here, we assessed the cross-reactivity of seasonal H3N2 and H1N1 and pandemic H1N1 influenza A virus-specific polyclonal CD8(+) T cells, obtained from HLA-typed study subjects, with the novel H7N9 virus. The cross-reactivity of CD8(+) T cells to H7N9 variants of known influenza A virus epitopes and H7N9 virus-infected cells was determined by their gamma interferon (IFN-γ) response and lytic activity. It was concluded that, apart from recognition of individual H7N9 variant epitopes, CD8(+) T cells to seasonal influenza viruses display considerable cross-reactivity with the novel H7N9 virus. The presence of these cross-reactive CD8(+) T cells may afford some protection against infection with the new virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.